Amneal Pharmaceuticals Inc (NYSE:AMRX) – Research analysts at SunTrust Banks reduced their Q3 2018 EPS estimates for shares of Amneal Pharmaceuticals in a research note issued to investors on Monday, November 5th. SunTrust Banks analyst J. Boris now anticipates that the company will post earnings per share of $0.26 for the quarter, down from their prior estimate of $0.27. SunTrust Banks has a “Hold” rating and a $15.00 price objective on the stock.
Other analysts have also recently issued reports about the stock. Royal Bank of Canada upgraded shares of Amneal Pharmaceuticals from a “sector perform” rating to an “outperform” rating in a research note on Monday, August 13th. BMO Capital Markets upped their price target on shares of Amneal Pharmaceuticals from $19.00 to $20.00 and gave the company a “market perform” rating in a research note on Friday, August 10th. Zacks Investment Research cut shares of Amneal Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 17th. Morgan Stanley dropped their price target on shares of Amneal Pharmaceuticals from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 3rd. Finally, B. Riley upped their price target on shares of Amneal Pharmaceuticals from $26.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, August 22nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $22.75.
Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings results on Wednesday, November 7th. The company reported $0.28 EPS for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.01. The company had revenue of $476.50 million for the quarter, compared to analysts’ expectations of $486.01 million. Amneal Pharmaceuticals had a negative net margin of 52.94% and a negative return on equity of 8.74%. The firm’s revenue was up 87.1% compared to the same quarter last year.
A number of institutional investors have recently bought and sold shares of the stock. Swiss National Bank increased its holdings in Amneal Pharmaceuticals by 48.2% during the 3rd quarter. Swiss National Bank now owns 182,100 shares of the company’s stock worth $4,041,000 after acquiring an additional 59,200 shares during the period. JPMorgan Chase & Co. increased its holdings in Amneal Pharmaceuticals by 12.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,155 shares of the company’s stock worth $536,000 after acquiring an additional 2,739 shares during the period. GW&K Investment Management LLC increased its holdings in Amneal Pharmaceuticals by 4.7% during the 3rd quarter. GW&K Investment Management LLC now owns 2,049,765 shares of the company’s stock worth $45,484,000 after acquiring an additional 92,859 shares during the period. Icon Advisers Inc. Co. increased its holdings in Amneal Pharmaceuticals by 11.3% during the 3rd quarter. Icon Advisers Inc. Co. now owns 32,500 shares of the company’s stock worth $721,000 after acquiring an additional 3,300 shares during the period. Finally, American Century Companies Inc. bought a new stake in Amneal Pharmaceuticals during the 3rd quarter worth approximately $1,326,000. 31.84% of the stock is currently owned by institutional investors and hedge funds.
In related news, SVP Nikita Shah sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $23.46, for a total transaction of $1,173,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Bryan M. Reasons sold 11,698 shares of the company’s stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $23.65, for a total transaction of $276,657.70. The disclosure for this sale can be found here. Corporate insiders own 3.20% of the company’s stock.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Featured Article: Are analyst ratings accurate?
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.